NCT03017521
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: AKT, PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have PI3K/AKT gene aberration
Exclusions: 
https://ClinicalTrials.gov/show/NCT03017521